Business Context and Reporting Period
Sight Sciences, Inc. (SGHT), a Delaware corporation, filed this Form 8-K on January 22, 2024, to report the entry into a material definitive agreement. The company is an emerging growth company headquartered in Menlo Park, California.
Key Financial Metrics and Transaction Details
The filing details a new senior secured term loan facility with Hercules Capital, Inc. Key financial terms include:
- Total Facility Size: Up to $65.0 million in aggregate principal.
- Initial Funding: $35.0 million funded on the closing date, yielding net proceeds of $34.6 million after costs.
- Debt Repayment: The company used proceeds to repay a prior term loan from MidCap Financial Trust totaling $37.7 million, including termination fees.
- Interest Rate: Floating rate based on the greater of 10.35% or the Wall Street Journal prime rate plus 2.35%. A default triggers an additional 3.0% per annum increase.
- Maturity Date: July 1, 2028.
- Exit Fee: 5.95% of originally funded Term Loans upon repayment.
- Equity Kickers: Warrants issued to purchase shares equal to 2% of the loan amount ($700,000 for the initial tranche) based on a 5-day VWAP. Warrants are exercisable for seven years.
- Prepayment Premiums: 3.0% (Year 1), 2.0% (Year 2), and 1.0% (thereafter).
Material Changes Versus Prior Period
The primary material change is the refinancing of the company's debt structure. The prior credit agreement with MidCap Financial Trust was terminated effective January 22, 2024, releasing MidCap's security interest in the company's assets. This was replaced by the new Hercules facility, which alters the company's interest rate structure, maturity profile, and covenant requirements.
Guidance, Covenants, and Risks
The new loan agreement imposes specific financial covenants and restrictions:
- Minimum Cash Covenant: The company must maintain unrestricted cash equal to at least 85% of total secured obligations. This requirement may be reduced to 35% upon achieving certain performance milestones.
- Minimum Revenue Covenant: Upon achieving milestones, the company must maintain trailing six-month GAAP revenue equal to 80% of the Board-approved forecast. This test is waived if the company maintains unrestricted cash equal to 100% of secured obligations, or 70% of obligations plus a market capitalization of at least $400 million.
- Negative Covenants: Restrictions on incurring new indebtedness, creating liens, engaging in mergers/acquisitions, changing business activities, and making restricted payments.
- Future Equity Rights: The lender has an option to invest up to $3 million in the company's next broadly marketed equity offering.
The filing does not provide specific revenue, profit, or cash flow figures for the reporting period, as this is a transactional report rather than a periodic financial statement.
Investor Verification Checklist
- Verify the company's current unrestricted cash balance against the 85% minimum cash covenant requirement.
- Confirm the status of performance milestones required to unlock additional tranches ($5.0M, $10.0M, and $15.0M) and reduce cash covenants.
- Review the impact of the 10.35% minimum interest rate on future interest expense compared to the prior MidCap facility.
- Assess the dilution impact of the warrants issued (2% of loan value) and the potential $3 million equity investment right granted to the lender.
- Monitor the company's ability to meet the revenue forecast covenant once triggered.